- CLINICAL BRIEFINGS
An engineered virus shows potential as an immune therapy in glioblastoma
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
doi: https://doi.org/10.1038/d41586-023-02944-4
‘Expert opinion’ and the figure are published under a CC BY 4.0 licence.
References
Vargas López, A. J. Neuro-oncology 23, 502–503 (2021).
Chuntova, P. et al. Neuro-oncology 23, 356–375 (2021).
Peruzzi, P. & Chiocca, E. A. Nature Rev. Clin. Oncol. 15, 657–658 (2018).
Chiocca, E. A., Nakashima, H., Kasai, K., Fernandez, S. A. & Oglesbee, M. Mol. Ther. Methods Clin. Dev. 17, 871–893 (2020).
Guerra, G. et al. Neuro-oncology 25, 1047–1057 (2023).